Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Eagle Pharmaceuticals (NQ: EGRX ) 4.530 +0.550 (+13.82%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Eagle Pharmaceuticals < Previous 1 2 3 4 5 6 Next > The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout October 05, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... Via Benzinga The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight August 08, 2021 Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... Via Benzinga Exposures Product Safety The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO October 01, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... Via Benzinga Exposures Product Safety Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021 September 07, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug September 30, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... Via Benzinga Exposures COVID-19 The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive September 28, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... Via Benzinga Eagle Pharmaceuticals to Present at September Healthcare Conferences September 01, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering September 01, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... Via Benzinga 33 Stocks Moving In Tuesday's Mid-Day Session August 31, 2021 Gainers AC Immune SA (NASDAQ: ACIU) shares jumped 68.4% to $11.77. AC Immune and its collaborating partner Genentech, part of Roche Holdings, announced topline data from Phase 2... Via Benzinga 55 Biggest Movers From Yesterday September 01, 2021 Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. (NASDAQ: ELYS) rose 43% to close at $6.62 after it... Via Benzinga Eagle Pharmaceuticals Wins Vasopressin Patent Trial August 31, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise August 31, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug August 25, 2021 ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... Via Benzinga Exposures COVID-19 Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia August 25, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire Eagle Pharmaceuticals, inc (EGRX) Q2 2021 Earnings Call Transcript August 09, 2021 EGRX earnings call for the period ending June 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus August 09, 2021 Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH for the commercial rights to its product,... Via Benzinga Topics Earnings Exposures Financial Recap: Eagle Pharmaceuticals Q2 Earnings August 09, 2021 Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 63.16% year over year to $0... Via Benzinga Eagle Pharmaceuticals Reports Second Quarter 2021 Results August 09, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker August 09, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021 July 28, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin June 24, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire Eagle Pharmaceuticals: Return On Capital Employed Insights June 22, 2021 During Q1, Eagle Pharmaceuticals (NASDAQ:EGRX) brought in sales totaling $41.25 million. However, earnings decreased 138.53%, resulting in a loss of $3.77 million. In Q4, Eagle... Via Benzinga Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin June 17, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire Return On Capital Employed Overview: Eagle Pharmaceuticals June 04, 2021 During Q1, Eagle Pharmaceuticals (NASDAQ:EGRX) brought in sales totaling $41.25 million. However, earnings decreased 138.53%, resulting in a loss of $3.77 million. Eagle... Via Benzinga Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021 May 26, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference May 11, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire Eagle Pharmaceuticals Inc (EGRX) Q1 2021 Earnings Call Transcript May 10, 2021 EGRX earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial Recap: Eagle Pharmaceuticals Q1 Earnings May 10, 2021 Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share decreased 71.43% year over... Via Benzinga Eagle Pharmaceuticals Reports First Quarter 2021 Results May 10, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion (“RI”) Liquid Formulation in Japan May 10, 2021 From Eagle Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.